Oncoral phase 1 results to be presented at ESMO congress in Munich

2018-09-10

About the Phase I study:

Oncoral has been evaluated in an investigator sponsored Phase I trial at the Department of Oncology at Herlev Hospital in Denmark. The study was a dose-escalating safety, tolerability and pharmacokinetics study of orally administered Oncoral in adult patients with advanced solid tumours. The objectives of the study were to determine the safety, tolerability and maximum tolerated dose of Oncoral given as single agent and when administered in combination with the oral chemotherapeutic drug capecitabine. Additional objectives were to determine any objective tumour response or stable disease, and to describe the pharmacokinetics of Oncoral given as single agent. A total of 25 patients were enrolled in the part of the study with Oncoral given as single agent.

The results of the combination study with capecitabine will be presented at a later stage.

For further information contact:
Magnus Corfitzen, CEO, +46 735 179 110

About Ascelia Pharma

Ascelia Pharma is a specialty pharmaceutical company dedicated to the development of novel medicines to improve the life expectancy and quality of life for people living with cancer. The company is located at Medeon Science Park in Malmö, Sweden in the middle of Medicon Valley, a leading European life science cluster. For more information, please visit http://www.ascelia.com 

Download as PDF

2019-05-23

Presentation from Avanza share day

2019-05-20

Ascelia Pharma to present at Avanza börsdag, 22 May 2019

On 22 May 2019, Ascelia Pharma’s CEO Magnus Corfitzen will present at the Avanza share seminar (“börsdag”). The presentation will be held at Operaterassen in Stockholm. Ascelia Pharma’s presentation starts at 9:45am CET and will also be broadcasted live as a webcast: https://tv.streamfabriken.com/2019-05-22-ascelia-pharma
2019-05-15

Q3 2018/2019 Financial Report (Jan-Mar 2019): Fully financed Phase III program for Mangoral through the IPO

Ascelia Pharma AB (publ) (ticker: ACE) today announced that its interim report for the period January-March 2019 is now available on the company’s website: https://www.ascelia.com/tag/reports-presentations/